Silver Point Capital L.P.: insider trades and track record
As of Aug 13, 2026, Silver Point Capital L.P. filed 6 open-market purchases worth $78M and 6 sales worth $407M in 4 companies since Dec 11, 2023, from Form 4 filings. At the latest insider trade price in each stock, 4 of 5 purchases are worth more than the price paid (median change +1%).
Latest filing Aug 13, 2026. From Form 4 filings. Data only, not investment advice.
At a glance
Track record by company
One row per company: what they paid, what they got for shares sold later, and how the shares they still hold compare with the latest insider trade price.
| Stock | Role | Bought | Avg price paid | Result on shares sold | Shares still held | Latest price | Change on held shares |
|---|---|---|---|---|---|---|---|
| Keenova Therapeutics plc | 10% owner | $69.2M | $91.60 | – | 755,500 | $91.00 Nov 10, 2026 | -1% |
| THS | 10% owner | $8.8M | $24.54 | – | 357,917 | no recent trade | – |
2.47M shares sold were not bought in the open market in our data (stock awards, options or purchases before Nov 17, 2023), so they have no return.
Every purchase and the latest price
Each open-market purchase, next to the most recent price any insider paid or received for the same stock.
| Date | Stock | Shares | Price paid | Value | Latest price | Change |
|---|---|---|---|---|---|---|
| May 20, 2026 | Keenova Therapeutics plc | 210,000 | $90.50 | $19M | $91.00 Nov 10, 2026 | +1% |
| May 19, 2026 | Keenova Therapeutics plc | 187,500 | $90.50 | $17M | $91.00 Nov 10, 2026 | +1% |
| Feb 10, 2026 | THS | 357,917 | $24.54 | $8.8M | no later trade | – |
| Nov 19, 2025 | Keenova Therapeutics plc | 42,000 | $88.88 | $3.7M | $91.00 Nov 10, 2026 | +2% |
| Nov 17, 2025 | Keenova Therapeutics plc | 26,000 | $88.88 | $2.3M | $91.00 Nov 10, 2026 | +2% |
| Nov 10, 2025 | Keenova Therapeutics plc | 290,000 | $93.75 | $27.2M | $91.00 Nov 10, 2026 | -3% |
How this track record is worked out
- Only open-market purchases and sales (Form 4 codes P and S) from the last 3 years. Shares received as pay, from options or before that window are not purchases, so they never count toward a return.
- Result on shares sold matches each sale with this insider's own earlier purchases in the same company, oldest first, using the prices in their filings.
- Latest price is the price of the most recent open-market trade any insider filed in that company, with its date. It is not a live stock quote, and it is not shown when it is more than 120 days old.
- Prices are adjusted for stock splits, found when the company's shares outstanding (from its 10-Q and 10-K covers) and the trade prices move by the same split ratio.
- A trade reported jointly by several owners (a fund, its manager, its partners) is shown once, under the first owner named in the filing.
- Past results say nothing about future trades. This is a record of filings, not a recommendation.
All open-market trades
Purchases and sales by month for the last 3 years. Click a month to see only its trades.
| Date | Stock | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | QVCG | Silver Point Capital L.P. +2 | 10% owner | Sale | 50,000 | $17.50 | $875K | Form 4 |
| May 20, 2026 | Keenova Therapeutics plc | Silver Point Capital L.P. +2 | 10% owner | Purchase | 210,000 | $90.50 | $19M | Form 4 |
| May 19, 2026 | Keenova Therapeutics plc | Silver Point Capital L.P. +2 | 10% owner | Purchase | 187,500 | $90.50 | $17M | Form 4 |
| Mar 3, 2026 | GPOR | Silver Point Capital L.P. +2 | Director | Sale | 84,416 | $204.22 | $17.2M | Form 4 |
| Mar 2, 2026 | GPOR | Silver Point Capital L.P. +2 | Director | Sale | 759,740 | $204.22 | $155M | Form 4 |
| Feb 10, 2026 | THS | Silver Point Capital L.P. +2 | 10% owner | Purchase | 357,917 | $24.54 | $8.8M | Form 4 |
| Nov 19, 2025 | Keenova Therapeutics plc | Silver Point Capital L.P. +2 | 10% owner | Purchase | 42,000 | $88.88 | $3.7M | Form 4 |
| Nov 17, 2025 | Keenova Therapeutics plc | Silver Point Capital L.P. +2 | 10% owner | Purchase | 26,000 | $88.88 | $2.3M | Form 4 |
| Nov 10, 2025 | Keenova Therapeutics plc | Silver Point Capital L.P. +2 | 10% owner | Purchase | 290,000 | $93.75 | $27.2M | Form 4 |
| Dec 19, 2024 | GPOR | Silver Point Capital L.P. +2 | Director | Sale | 529,410 | $162.81 | $86.2M | Form 4 |
| Mar 19, 2024 | GPOR | Silver Point Capital L.P. +2 | Director | Sale | 500,000 | $154.29 | $77.1M | Form 4 |
| Dec 11, 2023 | GPOR | Silver Point Capital L.P. +2 | Director | Sale | 550,000 | $128.21 | $70.5M | Form 4 |
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.